PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.69%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.94%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
1.43%
Gross profit growth 50-75% of Medical - Pharmaceuticals median of 2.29%. Guy Spier might worry about insufficient cost control or weaker pricing.
10.35%
EBIT growth of 10.35% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
2.77%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.87%. Joel Greenblatt would see if unique processes drive exceptional profitability.
10.77%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.35%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
10.76%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 2.30%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
10.76%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 2.32%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.52%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.47%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.00%
10Y CAGR of 25.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
-4.42%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 6.26%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-31.64%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 11.41%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
No Data
No Data available this quarter, please select a different quarter.
128.06%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 70.56% over a decade. Joel Greenblatt might see a standout compounder of earnings.
16.10%
5Y net income/share CAGR 50-75% of Medical - Pharmaceuticals median. Guy Spier might question fundamental disadvantages in cost structure or growth drivers.
-24.32%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 19.18%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
93.99%
Equity/share CAGR of 93.99% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
30.55%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 7.61%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
-14.41%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 6.54%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.45%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-2.50%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-0.38%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
3.50%
BV/share growth of 3.50% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-0.73%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
1.10%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.